Trial Profile
A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Berberine ursodeoxycholate (Primary) ; Ursodeoxycholic acid
- Indications Primary sclerosing cholangitis
- Focus Therapeutic Use
- Sponsors HighTide Biopharma
- 10 Feb 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Feb 2019 Planned End Date changed from 4 Nov 2019 to 4 Nov 2021.
- 24 Feb 2019 Planned primary completion date changed from 4 Oct 2019 to 4 Oct 2021.